We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Disinvestment Study of Population-Based Vision Screening in Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01675193
First Posted: August 29, 2012
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Public Health Service of Amsterdam
Icare Youth Health Care
Information provided by (Responsible Party):
Huib Simonsz, Erasmus Medical Center
  Purpose
The purpose of this study is to determine the optimal screening intervals and cost-effectiveness of population-based vision screening in preverbal children in the Netherlands.

Condition Intervention
Amblyopia Behavioral: Disinvestment protocol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Disinvestment Study of Population-Based Vision Screening in Preverbal Children in the Netherlands

Resource links provided by NLM:


Further study details as provided by Huib Simonsz, Erasmus Medical Center:

Primary Outcome Measures:
  • The number of cases of amblyopia detected, weighted for visual acuity, against age at detection. [ Time Frame: 2011-2016 ]
    The number of cases of amblyopia detected, weighted for visual acuity, against age at detection.


Secondary Outcome Measures:
  • Cost-effectiveness analysis of vision screening in the two regions under both scenarios, with and without screening at age 6-9 and 14-24 months. [ Time Frame: 2011-2016 ]
    Cost-effectiveness analysis of vision screening in the two regions under both scenarios, with and without screening at age 6-9 and 14-24 months.


Enrollment: 10803
Study Start Date: February 2012
Study Completion Date: May 1, 2017
Primary Completion Date: May 1, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Current screening protocol
Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
Disinvestment protocol
No eye screening at 6-9 and 14-24 months
Behavioral: Disinvestment protocol
Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months

Detailed Description:

Amblyopia (prevalence 3 - 4%)is a preventable, unilateral loss of vision in young children, in most cases caused by strabismus (squint) or unilateral hypermetropia (need of plus glasses), or both. The sensitive period in which vision loss can develop and be recovered, by covering the better eye with a patch, is up to 6 years of age. Population-based programs for child vision screening exist in Sweden, the United Kingdom, Canada, eastern European countries and the Netherlands. Measurement of visual acuity at age four (preschool) is most common. In some countries, including Canada and the Netherlands, preverbal screening of visual function in infants and young children (age 0 - 2) has been added to the screening program. In the Netherlands, it is applied during the regular visits at ages 1-2, 3-4, 6-9, 14-24 months. At the age of 36 months, monocular visual acuity is tested with a picture chart. At the age of 45 and 60 months, monocular visual acuity is measured with the Landolt-C chart. In 1996, the investigators started a follow-up study of a birth cohort in Rotterdam (RAMSES) to determine the sensitivity, specificity and effectiveness of the screening program. A diagnosis of amblyopia was made in 100 (3.4%) of 2,964 children and was caused by refractive error (42), strabismus (19), both combined (30) or deprivation (7). It was found that most cases of amblyopia were detected by vision screening with measurement of visual acuity from age 3 years onwards. Preverbal screening enabled earlier detection of strabismus amblyopia, but not at all of refractive amblyopia.

The investigators therefore propose a disinvestment study of vision screening, with omission of screening at age 6-9 and 14-24 months. First, the optimal screening intervals are calculated with a newly developed micro-simulation model for effectiveness of repeated screening, on the basis of the data obtained in the RAMSES study. The model simulation predicted that screening at age 6-9 and 14-24 months can be omitted without an appreciable loss of number of detected amblyopia cases. This will be tested in a RCT among two large youth health care organisations, ICARE (12,500 new children annually) and GGD-Amsterdam. Two large birth-cohorts will be recruited. Children born between July and December 2011 will form our control group and will be examined at 6-9, 14-24, 36 and 45 months. Children born between January and June 2012 will be our intervention group. These children will be examined only at 36 and 45 months.

Endpoint is the number of cases of amblyopia detected, weighted for visual acuity, against age at detection. The question is whether a significant difference between groups can be found in the cumulative number of cases of amblyopia detected up to the age of 4 years. The new model for optimising screening intervals will be developed further in the course of the study into a generic tool for determining optimal screening intervals in any screening program with repeated exams for young children and should ultimately allow for comparison of effectiveness of population-based screening programs for different disorders in different countries, carried out by different personnel. Finally, in the RAMSES study 23% of the children screened positively had not been referred successfully to an ophthalmologist or orthoptist; 43% of their parents had low to moderate fluency in the Dutch language. This reflects lack of utilisation among immigrants of preventive screening and a faltering transit from prevention to care. Unsuccessful referral, in relation to parental fluency in Dutch, ethnicity and SES will, hence, be monitored in the study in an exploratory fashion.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 14 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All children visiting the selected screening offices and becoming 6 months of age(in a 6 months period from the start of recruiting).

Exclusion Criteria:

  • previous eye surgery
  • previous eye disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01675193


Locations
Netherlands
GGD Jeugdzorg Amsterdam
Amsterdam, Netherlands
Icare Jeugdgezondheidszorg
Meppel, Netherlands
Sponsors and Collaborators
Erasmus Medical Center
Public Health Service of Amsterdam
Icare Youth Health Care
Investigators
Study Chair: Huibert J Simonsz, MD, PhD ErasmusMC, Department of Ophthalmology
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Huib Simonsz, Prof. H.J. Simonsz, MD, PhD, Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT01675193     History of Changes
Other Study ID Numbers: ErasmusMC MEC-2012-003
First Submitted: August 27, 2012
First Posted: August 29, 2012
Last Update Posted: August 22, 2017
Last Verified: August 2017

Keywords provided by Huib Simonsz, Erasmus Medical Center:
Amblyopia
Vision-Screening

Additional relevant MeSH terms:
Amblyopia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Eye Diseases
Signs and Symptoms